NDTVCenter·
'Potential Unknown': Cancer Drug Trial Rockets Moderna, But Draws Bearish Views For Merck
TD Cowen struck a cautious note on Merck shares at a target price of $137, marking a downside of nearly 10%.
Read at NDTV →
Business · 1 sources covering this
'Potential Unknown': Cancer Drug Trial Rockets Moderna, But Draws Bearish Views For Merck
TD Cowen struck a cautious note on Merck shares at a target price of $137, marking a downside of nearly 10%.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://hindustansphere.com/embed/cluster/43fb39f3446f46b61b7e2021cd76dfb913801732" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="'Potential Unknown': Cancer Drug Trial Rockets Moderna, But Draws Bearish Views For Merck"></iframe>
